A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of VRN101099 in Patients With HER2-Positive Solid Tumors
Latest Information Update: 12 Feb 2025
At a glance
- Drugs VRN 10 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Voronoi
Most Recent Events
- 12 Feb 2025 New trial record